Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories
In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories (NYSE: ABT).
Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.”
Abbott Laboratories closed on Friday at $65.53.
Latest Ratings for ABT
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.